G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 523.05 INR 0.11% Market Closed
Market Cap: 429.8B INR
Have any thoughts about
Glenmark Pharmaceuticals Ltd?
Write Note

Gross Margin
Glenmark Pharmaceuticals Ltd

63.9%
Current
64%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.9%
=
Gross Profit
76.9B
/
Revenue
120.2B

Gross Margin Across Competitors

Country IN
Market Cap 429.8B INR
Gross Margin
64%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.7B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 372B USD
Gross Margin
69%
Country US
Market Cap 257.3B USD
Gross Margin
77%
Country CH
Market Cap 201.7B CHF
Gross Margin
73%
Country UK
Market Cap 163B GBP
Gross Margin
82%
Country CH
Market Cap 179.6B CHF
Gross Margin
75%
Country US
Market Cap 146B USD
Gross Margin
71%
No Stocks Found

Glenmark Pharmaceuticals Ltd
Glance View

Market Cap
429.8B INR
Industry
Pharmaceuticals

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. The company focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. The company is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. The company is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.

GLENMARK Intrinsic Value
1 022.69 INR
Overvaluation 33%
Intrinsic Value
Price
G

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.9%
=
Gross Profit
76.9B
/
Revenue
120.2B
What is the Gross Margin of Glenmark Pharmaceuticals Ltd?

Based on Glenmark Pharmaceuticals Ltd's most recent financial statements, the company has Gross Margin of 63.9%.